| P/E (FY) | — | Sales (TTM) | $295.4M |
| Earnings (TTM) | -$49.7M | ROE | −28.23% |
| Net Margin | −21.48% | ROIC | −15.74% |
| Debt / Equity | 0.60 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 14.34% |
Adaptive Biotechnologies is a commercial-stage company developing an immune medicine platform for diagnosing and treating various diseases. Its immunosequencing platform combines proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data. The company's clonoSEQ diagnostic test detects and monitors residual cancer cells, known as Minimal Residual Disease. It offers products and services for life sciences research, clinical diagnostics, and drug discovery applications.
| Market Cap | $3.60B | Trading Days | 1778 |
| 52W High | 23.15 |
| 52W Low | 9.96 |
| % Off High | −2.72% |
| YTD | 38.67% | 1Y | 112.25% |
| 3Y | 179.06% | 5Y | −39.46% |
| Since incept. (ann.) | −7.88% |
Immune Medicine Service Revenue 100%
| Ann. Volatility (1Y) | 69.46% | Ann. Volatility (3Y) | 77.18% |
| Sharpe (1Y) | 1.44 | Sharpe (3Y) | 0.84 |
| Max Drawdown (1Y) | −39.35% | Max Drawdown (3Y) | −72.33% |
| Beta (3Y, vs SPY) | 2.05 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| SCNI | Scinai Immunotherapeutics Ltd. | $3.66B | — |
| RLAY | Relay Therapeutics, Inc. | $3.50B | — |
| DNLI | Denali Therapeutics Inc. | $3.82B | — |
| DBVT | DBV Technologies S.A. | $4.00B | — |
| CRSP | CRISPR Therapeutics AG | $4.59B | — |
| BEAM | Beam Therapeutics Inc. | $2.70B | — |
| TARS | Tarsus Pharmaceuticals, Inc. | $2.54B | — |
| KOD | Kodiak Sciences Inc. | $2.52B | — |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $2.48B | 8.0 |
| VCEL | Vericel Corp | $2.39B | 146.0 |
| TWST | Twist Bioscience Corp | $5.51B |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.35B | — |
